RE:RE:RE:RE:RE:RE:RE:RE:RE:2021 Year End Financial Resultswoundedknee wrote: There'll be lots of rain on your parade Mugsy. Seeing that the January update listed the phase 3 initiation in the second half of 2021 and now it goes to 1st Q of 2022. That's a fairly substantial delay as it could mean as much as 9 months. Of course that's if Dan is being upfront with us this time. As I've stated in the past I commend all those (including Dan) that have put in the long hours to bring this to the brink of a better and safer pain reliever. My beef is that I wish Dan would take a course on ethics and how important it is to be up front with shareholders. Yep..I can wait another year or whatever time we're looking at, but it doesn't go good with me when we have had two major insider sales in the last year, another significant delay, no reference to the Nasdaq and don't forget the surprise low dosing omission from the p2 trials. gl
You can complain all you want Wounded but if you have a problem with Dan - go see Dan.
Ask him about his ethics.
Leaving the personal attacks to those already on ignore.
---------------------------
Anyway ... what do we really know at this time ?
That's all I care about.
- AME studies begin the week of July 5 and are expected to end in Q4.
- Completion of single-dose IND-opening study with 24 subjects is in Q3 (don't know what this is) but I know there are small studies underway.
- FDA meeting in Q4.
- enrollment for Phase 3 is supposed to start by Christmas (as per Raymond James).
- Phase 3 is starting Q1 2022 (that's a new date).
- assuming NASDAQ is still likely in 2021 but they'll go when they see fit.
- working with CRO to extend patent life and move new drugs forward.
EOM